Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 10Neutropenia 8Breast Neoplasms 8Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

pegfilgrastim 7NPI 2358 4Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Docetaxel 3balugrastim 2Drug Therapy 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chemotherapy-induced Neutropenia × pegylated granulocyte colony-stimulating factor × Clear all
NCT03559387 2019-02-12

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Prolong Pharmaceuticals

Phase 2 Terminated
9 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡